1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Hemostats Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Prevalence of chronic disorders with increasing need for surgical interventions
5.1.1.2. Growing inclination toward minimally invasive surgeries
5.1.2. Restraints
5.1.2.1. Rising incidences of product recalls
5.1.3. Opportunities
5.1.3.1. Rise of biopolymer-based disposable hemostats
5.1.3.2. Integration of nanotechnology to create more efficient and targeted hemostats
5.1.4. Challenges
5.1.4.1. Risk of infection and cross contamination associated with the use of hemostats tools and reagents
5.2. Market Segmentation Analysis
5.2.1. Type: Expanding the use of combination hemostats owing to their enhanced effectiveness in minimizing bleeding
5.2.2. Formulation: Growing potential of powder hemostats for controlling and preventing bleeding during surgical intervention
5.2.3. Application: Significant role of hemostats in cardiovascular surgeries to prevent blood loss and ensure successful outcomes
5.3. Market Trend Analysis
5.3.1. Robust and improving healthcare infrastructure and availability of improved hemostats in the Americas region
5.3.2. Acceleration of medical tourism and expanding healthcare infrastructure with growing investment by the government in the Asia-Pacific
5.3.3. Increase in number of medical tourists coupled with strong foothold of major healthcare companies in the EMEA region
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Hemostats Market, by Type
6.1. Introduction
6.2. Collagen-Based Hemostats
6.3. Combination Hemostats
6.4. Gelatin-Based Hemostats
6.5. Oxidized Regenerated Cellulose-Based Hemostats
6.6. Thrombin-Based Hemostats
7. Hemostats Market, by Formulation
7.1. Introduction
7.2. Matrix & Gel Hemostats
7.3. Powder Hemostats
7.4. Sheet & Pad Hemostats
7.5. Sponge Hemostats
8. Hemostats Market, by Application
8.1. Introduction
8.2. Cardiovascular Surgery
8.3. General Surgery
8.4. Gynecological Surgery
8.5. Neurological Surgery
8.6. Orthopedic Surgery
8.7. Reconstructive Surgery
9. Americas Hemostats Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Hemostats Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Hemostats Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
12.3.1. Merger & Acquisition
12.3.1.1. Darling Ingredients Completes Acquisition of Brazilian Gelatin and Collagen Producer Gelnex
12.3.1.2. Hemostasis LLC Closes Acquisition of Fiagon Medical Technologies
12.3.2. New Product Launch & Enhancement
12.3.2.1. Baxter Launches PERCLOT Absorbable Hemostatic Powder
12.3.2.2. Olympus Europa SE & Co. KG Expands Endoclot Partnership with Endoclot to Launch Hemostatic Agents
12.3.3. Award, Recognition, & Expansion
12.3.3.1. Teleflex Receives FDA Clearance for Expanded Indication for QuikClot Control+ Hemostatic Device Usage in Cardiac Surgical Procedures
12.3.3.2. Artivion Gains FDA Approval for PerClot, Starts Transfer to Baxter
12.3.3.3. Chitosan-Based Hemostat For Controlling Severe Surgical Bleeding Gets FDA Clearance
12.3.3.4. Advamedica Inc Announces FDA Clearance for Ax-Surgi Surgical Hemostat
12.3.3.5. Medcura, Inc. Receives Breakthrough Device Designation for its LifeGel Absorbable Surgical Hemostat
12.3.3.6. Medtronic plc Nexpowder Endoscopic Hemostasis System Receives U.S. FDA Clearance
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. A.R. Medicom, Inc.
13.1.2. ACTEON Group
13.1.3. Advamedica Inc.
13.1.4. Advanced Medical Solutions Group PLC
13.1.5. Advin Health Care
13.1.6. Aegis Lifesciences Private Limited
13.1.7. Argon Medical Devices
13.1.8. B. Braun SE
13.1.9. Baxter International Inc.
13.1.10. Becton, Dickinson and Company
13.1.11. Betatech Medical
13.1.12. Convatec Group PLC
13.1.13. Cook Group Incorporated
13.1.14. Cortis Medtech Pvt Ltd
13.1.15. Cotran Corporation
13.1.16. Dolphin Sutures by Futura Surgicare Pvt. Ltd.
13.1.17. Dynarex Corporation
13.1.18. Gelita AG
13.1.19. Hangzhou Singclean Medical Products Co.,Ltd.
13.1.20. Healthium Medtech Ltd
13.1.21. Hemostasis, LLC
13.1.22. Integra LifeSciences Holdings Corporation
13.1.23. Johnson & Johnson Services, Inc.
13.1.24. Medcura, Inc.
13.1.25. Medline Industries, LP
13.1.26. Medprin Biotech GmbH
13.1.27. Medtronic PLC
13.1.28. Meril Life Sciences Pvt. Ltd.
13.1.29. Olympus Corporation
13.1.30. Pfizer Inc.
13.1.31. Rousselot BV by Darling Ingredients International Holding B.V.
13.1.32. Royal DSM
13.1.33. Shilpa Medicare Limited
13.1.34. Stapleline Medizintechnik GmbH
13.1.35. Stryker Corporation
13.1.36. SYMATESE
13.1.37. Teleflex Incorporated
13.1.38. Terumo Corporation
13.1.39. Zhejiang Perfectseal New Material Technology Co., Ltd.
13.1.40. Zimmer Biomet Holdings, Inc.
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
